Cabot (NYSE:CBT) Issues Quarterly Earnings Results

Cabot (NYSE:CBTGet Free Report) announced its earnings results on Monday. The specialty chemicals company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.02, FiscalAI reports. The company had revenue of $982.00 million for the quarter, compared to the consensus estimate of $943.16 million. Cabot had a net margin of 7.97% and a return on equity of 21.33%. Cabot updated its FY 2026 guidance to 6.150-6.450 EPS.

Cabot Stock Up 2.2%

Shares of CBT traded up $1.98 during midday trading on Monday, reaching $90.00. 550,866 shares of the stock were exchanged, compared to its average volume of 473,501. The company has a market cap of $4.65 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 11.46 and a beta of 0.83. The company has a quick ratio of 0.96, a current ratio of 1.45 and a debt-to-equity ratio of 0.51. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The firm has a 50 day simple moving average of $87.89 and a 200-day simple moving average of $79.43.

Cabot Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be paid a dividend of $0.4725 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.89 dividend on an annualized basis and a dividend yield of 2.1%. Cabot’s dividend payout ratio (DPR) is 35.73%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CBT. UBS Group lifted their price target on Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research report on Tuesday, May 26th. Wall Street Zen cut Cabot from a “buy” rating to a “hold” rating in a research note on Saturday. Mizuho upped their target price on Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Finally, Truist Financial began coverage on shares of Cabot in a research report on Monday, June 8th. They issued a “buy” rating and a $98.00 price target for the company. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $85.80.

Get Our Latest Report on Cabot

Hedge Funds Weigh In On Cabot

Hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its stake in Cabot by 2,559.5% in the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after acquiring an additional 947 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cabot by 3.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Cabot by 409.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the last quarter. Institutional investors and hedge funds own 93.18% of the company’s stock.

About Cabot

(Get Free Report)

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

Featured Articles

Earnings History for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.